6MW3211
Sponsors
Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions
Advanced Clear Cell Renal Cell CarcinomaAdvanced Lung CancerLymphoma
Phase 2
A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer
NCT05431569
Start: 2022-07-10End: 2023-09-10Target: 36Updated: 2022-06-24
A Clinical Study of 6MW3211 in Patients With Renal Cancer
NCT05440045
Start: 2022-09-01End: 2024-09-01Target: 30Updated: 2022-08-17
A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma
NCT05446688
Start: 2022-09-01End: 2024-09-01Target: 40Updated: 2022-07-07